4//SEC Filing
aTYR PHARMA INC 4
Accession 0000904454-15-000286
$ATYRCIK 0001339970operating
Filed
May 11, 8:00 PM ET
Accepted
May 12, 9:41 PM ET
Size
21.6 KB
Accession
0000904454-15-000286
Insider Transaction Report
Form 4
aTYR PHARMA INCLIFE
Domain Partners VIII, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2015-05-12+1,807,820→ 1,807,820 total - Conversion
Series C Preferred Stock
2015-05-12−12,143,933→ 0 total→ Common Stock (1,526,745 underlying) - Conversion
Series D Preferred Stock
2015-05-12−1,506,901→ 0 total→ Common Stock (189,449 underlying) - Conversion
Series E Preferred Stock
2015-05-12−887,073→ 0 total→ Common Stock (91,626 underlying)
DOVEY BRIAN H
10% Owner
Transactions
- Conversion
Common Stock
2015-05-12+1,807,820→ 1,807,820 total - Conversion
Series C Preferred Stock
2015-05-12−12,143,933→ 0 total→ Common Stock (1,526,745 underlying) - Conversion
Series D Preferred Stock
2015-05-12−1,506,901→ 0 total→ Common Stock (189,449 underlying) - Conversion
Series E Preferred Stock
2015-05-12−887,073→ 0 total→ Common Stock (91,626 underlying)
TREU JESSE I
10% Owner
Transactions
- Conversion
Common Stock
2015-05-12+1,807,820→ 1,807,820 total - Conversion
Series E Preferred Stock
2015-05-12−887,073→ 0 total→ Common Stock (91,626 underlying) - Conversion
Series D Preferred Stock
2015-05-12−1,506,901→ 0 total→ Common Stock (189,449 underlying) - Conversion
Series C Preferred Stock
2015-05-12−12,143,933→ 0 total→ Common Stock (1,526,745 underlying)
BLAIR JAMES C
Director10% Owner
Transactions
- Conversion
Common Stock
2015-05-12+1,807,820→ 1,807,820 total - Conversion
Series C Preferred Stock
2015-05-12−12,143,933→ 0 total→ Common Stock (1,526,745 underlying) - Conversion
Series D Preferred Stock
2015-05-12−1,506,901→ 0 total→ Common Stock (189,449 underlying) - Conversion
Series E Preferred Stock
2015-05-12−887,073→ 0 total→ Common Stock (91,626 underlying)
SCHOEMAKER KATHLEEN K
10% Owner
Transactions
- Conversion
Common Stock
2015-05-12+1,807,820→ 1,807,820 total - Conversion
Series C Preferred Stock
2015-05-12−12,143,933→ 0 total→ Common Stock (1,526,745 underlying) - Conversion
Series E Preferred Stock
2015-05-12−887,073→ 0 total→ Common Stock (91,626 underlying) - Conversion
Series D Preferred Stock
2015-05-12−1,506,901→ 0 total→ Common Stock (189,449 underlying)
VITULLO NICOLE
10% Owner
Transactions
- Conversion
Common Stock
2015-05-12+1,807,820→ 1,807,820 total - Conversion
Series C Preferred Stock
2015-05-12−12,143,933→ 0 total→ Common Stock (1,526,745 underlying) - Conversion
Series E Preferred Stock
2015-05-12−887,073→ 0 total→ Common Stock (91,626 underlying) - Conversion
Series D Preferred Stock
2015-05-12−1,506,901→ 0 total→ Common Stock (189,449 underlying)
Halak Brian K
10% Owner
Transactions
- Conversion
Series C Preferred Stock
2015-05-12−12,143,933→ 0 total→ Common Stock (1,526,745 underlying) - Conversion
Series E Preferred Stock
2015-05-12−887,073→ 0 total→ Common Stock (91,626 underlying) - Conversion
Common Stock
2015-05-12+1,807,820→ 1,807,820 total - Conversion
Series D Preferred Stock
2015-05-12−1,506,901→ 0 total→ Common Stock (189,449 underlying)
Footnotes (7)
- [F1]All outstanding Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.
- [F2]These shares converted into Common Stock on a 1-for-7.95413 basis.
- [F3]These shares converted into Common Stock on a 1-for-9.6814 basis.
- [F4]The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
- [F5]As managing members of the sole general partner of DP VIII Associates, L.P., each Reporting Owner listed below may also be deemed to indirectly beneficially own 13,414 shares of Common Stock held by DP VIII Associates, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by DP VIII Associates, L.P., however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
- [F6]As managing members of Domain Associates, LLC, each Reporting Owner listed below may also be deemed to indirectly beneficially own 6,286 shares of Common Stock held by Domain Associates, LLC. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by Domain Associates, LLC, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
- [F7]James C. Blair also directly beneficially owns 6,286 shares of Common Stock.
Documents
Issuer
aTYR PHARMA INC
CIK 0001339970
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001339970
Filing Metadata
- Form type
- 4
- Filed
- May 11, 8:00 PM ET
- Accepted
- May 12, 9:41 PM ET
- Size
- 21.6 KB